News
Eric Green, M.D., Ph.D., formerly the NHGRI director, has been awarded by Fierce Pharma as a Fierce 50 Innovation Honoree. The Fierce 50 is designed to honor the 50 most influential leaders and organizations shaping the future of biopharma, healthcare, and life sciences. The Fierce editorial team
The National Cancer Institute (NCI) is seeking a collaboration partner for a COVID-19 therapeutic that will stop the infected cells from replicating inside a host. When SARS-CoV-2 enters a host, the cells replicate it and viral particles invade the nearby healthy cells. This happens because SARS-CoV
Louis Staudt, M.D., Ph.D. was recently awarded the Career Achievement Award, which recognizes ten or more years in HHS and dedication and loyalty to the Department. Dr. Staudt is the Chief of the Lymphoid Malignancies Branch at NCI. Dr. Staudt pioneered the use of gene expression profiling to
The National Institute of Dental and Craniofacial Research (NIDCR) at the NIH has a great non-exclusive license opportunity available to commercialize a novel adeno-associated virus termed “44-9” (AAV44-9) vector for gene therapy. AAV44-9 based vectors have high gene transfer activity in many cell